Metrics as of 10/13/2026, 06:36 PM (Berlin time), refresh in progress.
Zenas BioPharma Stock
Zenas BioPharma, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Leon Oliver Moulder Jr.
- Employees
- 167
- Market cap
- $1.6 B
- IPO
- 13/09/2024
- Web
- zenasbio.com
Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company based in the United States that focuses on the creation and market introduction of innovative immunology-based treatments. Headquartered in Waltham, Massachusetts, the entity was established in 2019 and previously operated as Zenas BioPharma (Cayman)…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Zenas BioPharma stock: price history
1D
-0.4%
1W
-11.1%
1M
-21.5%
6M
+19.0%
YTD
-31.0%
1Y
-3.1%
2Y
+33.6%
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~35% weaker price swings than usual
Ask the agents about Zenas BioPharma
Analyst assessment of Zenas BioPharma
PRICE TARGET LOW
US$32.00
CONSENSUS
US$43.50
MEDIAN
US$43.50
PRICE TARGET HIGH
US$55.00
0
STRONG BUY
4
BUY
1
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 30/09/2026
Zenas BioPharma stock metrics
P/E
-2.6
P/B
6.4
EV/EBITDA
-3.88
RETURN ON EQUITY
-45.1%
NET MARGIN
-11,145.6%
DEBT/EQUITY
1.58
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
23.4%
FLOAT SHARES
14,799,443
AVG. DAILY VOLUME (30D)
670,716
Insider transactions (SEC)
Fox Jennifer A.
Farmer Joseph L
MOULDER LEON O JR
MOULDER LEON O JR
MOULDER LEON O JR
Institutional holders
Comparable stocks
Frequently asked questions about Zenas BioPharma stock
What does Zenas BioPharma do?
Zenas BioPharma, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Leon Oliver Moulder Jr., the company employs around 167 people.
The IPO was on 13/09/2024; the stock trades on NASDAQ under the ticker ZBIO.
What do analysts say about Zenas BioPharma stock?
5 analysts rate the stock, the consensus is Buy (as of 30/09/2026).
The average price target is US$43.50, ranging from US$32.00 to US$55.00, with a median of US$43.50.
This is an external assessment, not a statement by Market Jury.
When does Zenas BioPharma report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -35% stronger than usual.
Does Zenas BioPharma pay a dividend?
No, Zenas BioPharma currently does not pay a dividend.
Which stocks are comparable to Zenas BioPharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Zenas BioPharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Zenas BioPharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.